scholarly journals Differences in Decisional Regret among Patients Undergoing Elective and Non-elective Colectomy

2021 ◽  
Vol 233 (5) ◽  
pp. S54
Author(s):  
Alisha Lussiez ◽  
Maia Anderson ◽  
Lindsay Janes ◽  
Quintin P. Solano ◽  
Ryan A. Howard ◽  
...  
2019 ◽  
Vol 104 (2) ◽  
pp. 383-391 ◽  
Author(s):  
Pragati G. Advani ◽  
Xiudong Lei ◽  
Cameron W. Swanick ◽  
Ying Xu ◽  
Yu Shen ◽  
...  

2004 ◽  
Vol 199 (6) ◽  
pp. 904-912 ◽  
Author(s):  
Leon Salem ◽  
David L. Veenstra ◽  
Sean D. Sullivan ◽  
David R. Flum

2021 ◽  
Author(s):  
William J. Kane ◽  
Kevin T. Lynch ◽  
Taryn E. Hassinger ◽  
Sook C. Hoang ◽  
Charles M. Friel ◽  
...  

2017 ◽  
Vol 35 (5_suppl) ◽  
pp. 106-106
Author(s):  
Samantha Rose Dewald ◽  
Loki Natarajan ◽  
Irene Su

106 Background: Fertility is important to many young breast cancer survivors (YBCS), who face difficult decisions on whether to undergo fertility preservation prior to treatment. Because few longitudinal data assessing decisional regret are available, the objectives of this study were to assess longitudinal changes in decisional regret on fertility preservation following breast cancer diagnosis; determine if fertility preservation treatment decisions are related to decreased decisional regret. Methods: From 3 academic breast cancer programs, 169 YBCS younger than age 45 were recruited at diagnosis between 2009 and 2012 and followed prospectively for ovarian function. Participants completed questionnaires on fertility preservation choices and the Decisional Regret Scale (DRS) during study visits every 6 months for up to 5 years. DRS is scored 0 (no regret) to 100 (highest regret). DRS was dichotomized as none versus any decisional regret. Generalized linear models estimated the change in DRS over time and the association between patient characteristics and DRS. Results: Mean age at diagnosis was 38.7 (SD 4.8). Median total follow-up was 176 days (IQR 84 to 1415 days). Enrollment DRS was available for 89 women; 48% reported decisional regret about fertility preservation (median DRS=20). Participants worried about future fertility were more likely to report decisional regret (p=0.009). 31% underwent fertility preservation, but this was not associated with decisional regret (p=0.65). In repeated measures analysis for the entire cohort, no significant change in DRS occurred over this time period (OR 0.8, 95% CI 0.4-1.7). Worry about future fertility remained significantly associated with DRS over time (OR 55.1, 95% CI 7.7-395.1). Conclusions: In a cohort of YBCS, experiencing decisional regret about fertility preservation persists for years after diagnosis. Those worried about future fertility are more likely to experience decisional regret regarding fertility preservation.


2021 ◽  
pp. 1-6
Author(s):  
Luka Flegar ◽  
Martin Baunacke ◽  
Bjoern Thorben Buerk ◽  
Rick Proschmann ◽  
Aristeidis Zacharis ◽  
...  

<b><i>Purpose:</i></b> The aim of the study was to assess quality of life (QoL), decision involvement, and decisional regret after treatment with vascular-targeted photodynamic therapy (VTP) (TOOKAD®) for unilateral low-risk prostate cancer. <b><i>Methods:</i></b> Validated questionnaires (EORTC QLQ-C30 and QLQ-PR25) capturing QoL post-treatment, involvement in decision-making (Control Preferences Scale) and decision regret (Decisional Regret Scale), were given to patients at the 12-month visit after undergoing VTP at our institution between May 2018 and February 2021. <b><i>Results:</i></b> Out of 44 patients, 36 patients were included in this study and 31 (86.1%) responded to the questionnaires. Mean overall health score capturing QoL at 12 months was 79.3 (standard deviation: ±18.1). 70.9% of the patients (<i>n</i> = 22) had no decision regret, and 67.8% of men (<i>n</i> = 21) had an active role in decision-making. In control biopsy at 12 months post-treatment, 19.4% of patients (<i>n</i> = 7) presented with local recurrence and progression to higher Gleason score (GS) was found in 13.8% of patients (<i>n</i> = 5). Patients (<i>n</i> = 3) presenting with tumor recurrence or progression to higher GS in control biopsy showed a significantly higher level of decision regret (<i>p</i> &#x3c; 0.009). <b><i>Conclusion:</i></b> Only 9.7% of men (<i>n</i> = 3) felt a strong emotion of regret at 12 months after VTP. Level of decision regret was significantly higher in patients with local recurrence or tumor progression detected in control biopsy. QoL was stable after VTP.


2018 ◽  
Vol 61 (5) ◽  
pp. 593-598 ◽  
Author(s):  
Matthew Skancke ◽  
Khashayar Vaziri ◽  
Bindu Umapathi ◽  
Richard Amdur ◽  
Michal Radomski ◽  
...  

2016 ◽  
Vol 223 (4) ◽  
pp. S63-S64
Author(s):  
Zhaomin Xu ◽  
Geoffrey C. Williams ◽  
Christopher T. Aquina ◽  
Adan Z. Becerra ◽  
Bradley J. Hensley ◽  
...  

2012 ◽  
Vol 10 (10) ◽  
pp. 607-610 ◽  
Author(s):  
Daniel Lemanu ◽  
Sanket Srinivasa ◽  
Primal Singh ◽  
Arman Kahokehr ◽  
Kamran Zargar-Shoshtari ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document